Agile Therapeutics, Inc. (NASDAQ:AGRX) headquartered in Princeton, will host a conference call for the investment community to discuss the 3Q20 financial results on 12th November 2020 at 4:30 PM Eastern Time.
The conference call will also be webcast live under the investor relations section of the website www.agiletherapeutics.com
To participate on the live call, please dial (877) 407-2991 or (201) 389-0925 (International)
Earnings Expectation
Agile Therapeutics, Inc. is reporting third quarter financial results on Thursday 12th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, AGRX is expected to report 3Q20 loss of $ 0.18 per share. For the full year, analysts anticipate top line of $ 1.65 million, while looking forward to loss of $ 0.64 per share bottom line.
Agile Therapeutics, Inc., a womens healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch, which completed Phase III clinical trials. The company is also developing a pipeline of other transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; AG200-ER (SmP), a regimen to allow a woman to extend the length of her cycle, as well as experience shorter and lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.